<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19266" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cetirizine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Naqvi</surname>
            <given-names>Aasim</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gerriets</surname>
            <given-names>Valerie</given-names>
          </name>
          <aff>California Northstate University College of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aasim Naqvi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Valerie Gerriets declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>6</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19266.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This activity discusses&#x000a0;using cetirizine for allergic rhinitis and urticaria, shedding light on its indications, mechanism of action, and contraindications. Initially approved by the FDA in 1995 as a prescription-only medication, cetirizine gained over-the-counter status in 2007. This&#x000a0;discussion also&#x000a0;navigates the adverse event profile and other critical aspects, including&#x000a0;off-label uses, dosing, pharmacokinetics, monitoring, and relevant drug interactions, highlighting the role of the interprofessional healthcare team in overseeing therapy. Understanding cetirizine's&#x000a0;pharmacology empowers healthcare professionals to tailor treatment plans to individual patient needs. Equipped with evidence-based medicine, they can make informed decisions and fine-tune dosage regimens while mitigating adverse reactions.&#x000a0;By enhancing comprehension of cetirizine's pharmacological nuances, this educational initiative aims to elevate patient outcomes in allergic conditions, emphasizing the collaborative effort of the healthcare team in optimizing treatment strategies.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the mechanism of action of cetirizine.</p></list-item><list-item><p>Evaluate&#x000a0;the adverse effects of cetirizine.</p></list-item><list-item><p>Assess&#x000a0;the clinical monitoring parameters&#x000a0;for&#x000a0;cetirizine.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve patient outcomes and treatment efficacy while educating about potential adverse effects of cetirizine, such as drowsiness and fatigue.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19266&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19266">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19266.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cetirizine was FDA-approved in the United States as a prescription-only&#x000a0;product in 1995.&#x000a0;In 2007, it&#x000a0;was approved as an over-the-counter medication. Derived from the first-generation antihistamine hydroxyzine, cetirizine does not cross the blood-brain barrier to the extent of its first-generation counterparts. As a result, cetirizine is an effective treatment of allergic rhinitis that simultaneously minimizes the possibility of adverse sedative effects. In addition, cetirizine is a second-generation antihistamine that effectively relieves sneezing, rhinorrhea, and watery eyes associated with seasonal allergies and allergic rhinitis due to allergens such as dust mites and molds.&#x000a0;Additionally, cetirizine is available as a prescription-only ophthalmic formulation to treat allergic conjunctivitis.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cetirizine is an FDA-approved medication for the relief and treatment of allergic rhinitis and chronic urticaria.<xref ref-type="bibr" rid="article-19266.r1">[1]</xref><xref ref-type="bibr" rid="article-19266.r2">[2]</xref>&#x000a0;The American Academy of Otolaryngology&#x000a0;suggests&#x000a0;cetirizine for seasonal and perennial allergic rhinitis.<xref ref-type="bibr" rid="article-19266.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Cetirizine effectively reduces the severity of hives and pruritus in patients with idiopathic urticaria.<xref ref-type="bibr" rid="article-19266.r4">[4]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Second-generation antihistamines like cetirizine are safe and effective&#x000a0;treatment options&#x000a0;in patients with&#x000a0;chronic urticaria&#x000a0;and are considered first-line agents by the&#x000a0;AAAAI and&#x000a0;ACAAI guidelines.<xref ref-type="bibr" rid="article-19266.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Cetirizine is considered safe for&#x000a0;perennial allergic rhinitis and urticaria in adults and children&#x000a0;older than 6 months; it is indicated for treating seasonal allergies in adults and children&#x000a0;2 years and older.</p>
          </list-item>
          <list-item>
            <p>The ophthalmic formulation of cetirizine is FDA-approved to treat allergic conjunctivitis.<xref ref-type="bibr" rid="article-19266.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>The FDA has approved the intravenous formulation of cetirizine for treating acute urticaria.<xref ref-type="bibr" rid="article-19266.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cetirizine is used as an adjunct to epinephrine (off-label) for the management of anaphylaxis. (The American Academy of Allergy, Asthma &#x00026; Immunology (AAAAI) and the American College of Allergy, Asthma&#x000a0;&#x00026; Immunology (ACAAI) guidelines).<xref ref-type="bibr" rid="article-19266.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Cetirizine is effective in infusion-related reactions due&#x000a0;to ocrelizumab&#x000a0;and non-inferior to diphenhydramine.<xref ref-type="bibr" rid="article-19266.r9">[9]</xref> Research has demonstrated the efficacy of cetirizine as a premedication agent for preventing hypersensitivity reactions induced by chemotherapy.<xref ref-type="bibr" rid="article-19266.r10">[10]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>BASCULE syndrome is characterized by Bier anemic spots, cyanosis, and urticaria-like eruption.&#x000a0;In a retrospective chart review of&#x000a0;patients with BASCULE syndrome, treatment responses to propranolol and high-dose cetirizine were noted.<xref ref-type="bibr" rid="article-19266.r11">[11]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A recent study suggests that topical cetirizine 1%&#x000a0;could be a potential treatment for androgenic alopecia,&#x000a0;especially for individuals who show poor responsiveness to topical minoxidil. Further&#x000a0;research&#x000a0;is needed to confirm these findings.<xref ref-type="bibr" rid="article-19266.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19266.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cetirizine is a fast-acting, highly selective peripheral histamine H1-receptor antagonist. The H1-receptors inhibited by cetirizine are primarily on respiratory smooth muscle cells, vascular endothelial cells, immune cells, and the gastrointestinal tract. Unlike first-generation antihistamines such as diphenhydramine and doxylamine, cetirizine does not cross the blood-brain barrier to a large extent, avoiding the neurons of the central nervous system. As a result, cetirizine produces minimal sedation compared to many first-generation antihistamines.<xref ref-type="bibr" rid="article-19266.r13">[13]</xref></p>
        <p>Given its antagonism with histamine H1-receptors, cetirizine effectively reverses many of the effects of histamine. Like other second-generation antihistamines, cetirizine decreases vascular permeability, decreasing fluid escaping to tissues from capillaries. Cetirizine is also an inhibitor of histamine-induced bronchospasm.<xref ref-type="bibr" rid="article-19266.r14">[14]</xref></p>
        <p>Cetirizine has&#x000a0;demonstrated significant anti-inflammatory activity, reducing the infiltration of inflammatory cells in allergic rhinitis.<xref ref-type="bibr" rid="article-19266.r15">[15]</xref> Specifically, research has found that cetirizine minimizes the migration of neutrophils and eosinophils.<xref ref-type="bibr" rid="article-19266.r16">[16]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Cetirizine is absorbed rapidly in the gastrointestinal tract and undergoes substantial excretion by the kidney. Cetirizine reaches peak plasma concentration after approximately&#x000a0;1 hour. The effects of cetirizine typically begin after 20 to 60 minutes and persist for at least 24 hours. Food does not affect&#x000a0;the extent of exposure (AUC) of cetirizine, but the time to attain peak concentration&#x000a0;is delayed by 1.7 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;The mean plasma protein binding of cetirizine is 93%.</p>
        <p><bold>Metabolism:</bold> Cetirizine undergoes oxidative O-dealkylation to a metabolite with negligible antihistaminic activity. Cetirizine is not a&#x000a0;substrate of the CYP450 system.<xref ref-type="bibr" rid="article-19266.r17">[17]</xref><xref ref-type="bibr" rid="article-19266.r18">[18]</xref>&#x000a0;Evidence indicates that cetirizine&#x000a0;is a P-glycoprotein substrate, which should be&#x000a0;considered in patients using cetirizine&#x000a0;concurrently with P-gp&#x000a0;inhibitors.<xref ref-type="bibr" rid="article-19266.r19">[19]</xref></p>
        <p><bold>Excretion:</bold> The elimination half-life of cetirizine&#x000a0;is 8.3 hours. Cetirizine&#x000a0;is primarily excreted through&#x000a0;the kidney.<xref ref-type="bibr" rid="article-19266.r20">[20]</xref></p>
      </sec>
      <sec id="article-19266.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Cetirizine is available as oral tablets, capsules,&#x000a0;solutions, and orally disintegrating tablets. The dosing of cetirizine depends on the patient's age. In adults and children 12 years or older, the recommended dose is 5 to 10 mg/d orally, depending on symptom severity.<xref ref-type="bibr" rid="article-19266.r21">[21]</xref>&#x000a0;Cetirizine is available in 5 mg and 10 mg tablets and 5 mg/5 mL oral solution and elixir. The ophthalmic formulation is 0.24% cetirizine hydrochloride eye drops in 5 mL and 7.5 mL bottles.&#x000a0;Cetirizine 5 mg combined with pseudoephedrine HCl 120 mg is a nasal decongestant that temporarily relieves sinus congestion and pressure.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Children 6 to 11 years old: 5 to 10 mg (1 or 2 teaspoons) once daily in syrup form is recommended, depending on symptom severity.<xref ref-type="bibr" rid="article-19266.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Children 2 to 5 years old: 2.5 mg (half a teaspoon) in syrup form once daily.</p>
          </list-item>
          <list-item>
            <p>Children&#x000a0;6 months to 23 months old: the recommended dose is 2.5 mg (half teaspoon) in syrup form once daily.</p>
          </list-item>
          <list-item>
            <p>One drop (0.24% cetirizine hydrochloride ophthalmic solution) is instilled in the affected eye twice daily for patients with allergic conjunctivitis.</p>
          </list-item>
          <list-item>
            <p>The FDA has approved the IV&#x000a0;administration of cetirizine 10 mg to treat acute urticaria in adults and adolescents aged 12 and older.</p>
          </list-item>
        </list>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <p><bold>Breastfeeding Considerations:</bold> Occasional and small doses of cetirizine are acceptable while breastfeeding. Prolonged use of larger doses may cause a decrease in the milk supply or drowsiness and other adverse effects in the infant, particularly when combined with pseudoephedrine. The use of an ophthalmic formulation of cetirizine by the mother&#x000a0;is&#x000a0;thought to&#x000a0;have minimal&#x000a0;risk to the breastfed infant. Clinicians should advise the mother to apply pressure over the tear duct by the corner of the eye and remove the leftover solution to&#x000a0;decrease the drug that reaches the breast milk.<xref ref-type="bibr" rid="article-19266.r23">[23]</xref></p>
        <p><bold>Pregnancy Considerations:</bold>&#x000a0;Cetirizine&#x000a0;is a former U.S. FDA pregnancy category B medicine.<bold>&#x000a0;</bold>The American College of Obstetricians and Gynecologists and the American College of Allergy, Asthma, and Immunology (ACOG-ACAAI)&#x000a0;recommend cetirizine for pregnant women who require antihistamine treatment.&#x000a0;Cetirizine should be used in pregnancy only when necessary.<xref ref-type="bibr" rid="article-19266.r24">[24]</xref><xref ref-type="bibr" rid="article-19266.r25">[25]</xref></p>
        <p><bold>Hepatic Impairment:</bold> According to the manufacturer's prescribing information, the dose for 12-year-old and older patients with hepatic impairment should be reduced to 5 mg daily. The manufacturer also recommends lowering the dose for patients 6 to 11 years old with hepatic impairment.&#x000a0;Intravenous&#x000a0;administration of cetirizine is intended for short-term use; no dose adjustment is required per the manufacturer's labeling.</p>
        <p><bold>Renal Impairment:</bold>&#x000a0;Manufacturers' prescribing information suggests reducing the dose to 5 mg daily for patients aged 12 years and older with decreased renal function (CrCL 11 to 31 mL/min) and patients on hemodialysis. The manufacturer also recommends lowering the dose for 6 to&#x000a0;11-year-old patients with renal impairment. The IV formulation of cetirizine is intended for short-term use; no dose adjustment is required per the manufacturer's labeling.</p>
        <p><bold>Pediatric Patients:</bold>&#x000a0;According to one meta-analysis, there is moderate to low certainty evidence that cetirizine may improve clinical outcomes and quality of life in children with allergic rhinitis. Cetirizine&#x000a0;demonstrates&#x000a0;comparable efficacy with other antihistamines and is generally well tolerated, although there is an increased risk of somnolence in the pediatric population.<xref ref-type="bibr" rid="article-19266.r26">[26]</xref>&#x000a0;The intravenous formulation is FDA-approved for urticaria in children 6 months and older.&#x000a0;For adolescents aged 12 years and older, the recommended intravenous dosage of cetirizine is 10 mg. Children aged 6 to 11 years old may receive either 5 mg to 10 mg, depending on symptom severity. For children aged 6 months to 5 years, the recommended intravenous dosage is 2.5 mg.</p>
        <p><bold>Older Patients:&#x000a0;</bold>Efficacy evaluations did not include an adequate number of patients aged 65 years and older to determine potential divergent response patterns compared to younger patients. Safety assessments of cetirizine in older patients compared to younger&#x000a0;adults&#x000a0;revealed no significant differences. However, sensitivity to adverse drug reactions in certain older individuals remains a possibility.</p>
        <p><bold>Ophthalmic Formulation:</bold> Each bottle of 0.24% cetirizine hydrochloride contains benzalkonium chloride and can be absorbed by contact lenses. Manufacturers advise patients to remove contact lenses and wait 10 minutes after administration until the reinsertion of lenses. If irritation or redness persists after this precaution, contact lenses should be avoided.&#x000a0;Cetirizine has proven safe and effective for pediatric patients&#x000a0;2 years and&#x000a0;older in clinical studies.<xref ref-type="bibr" rid="article-19266.r27">[27]</xref></p>
      </sec>
      <sec id="article-19266.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Cetirizine is safe and relatively well-tolerated for treating allergic rhinitis and urticaria. Although uncommon, its primary adverse effects in adults include somnolence, fatigue, pharyngitis, dizziness, and dry mouth.<xref ref-type="bibr" rid="article-19266.r1">[1]</xref></p>
        <p>Somnolence appears to be a dose-related effect of cetirizine. Research indicates that in some patients, cetirizine contributes to daytime sleepiness.<xref ref-type="bibr" rid="article-19266.r28">[28]</xref></p>
        <p>Children taking cetirizine&#x000a0;most commonly experience similar side effects as adults taking cetirizine (eg, somnolence, fatigue, and dry mouth). Children, in particular, are more likely than adults to experience headaches while taking cetirizine.<xref ref-type="bibr" rid="article-19266.r29">[29]</xref></p>
        <p>In pediatric patients aged 2 to 11, the majority of adverse reactions reported with cetirizine were mild or moderate. Somnolence appeared to be dose-related, and&#x000a0;abdominal pain was considered treatment-related.</p>
        <p>Common&#x000a0;adverse drug reactions of cetirizine ophthalmic solution are conjunctival hyperemia and instillation site pain.<xref ref-type="bibr" rid="article-19266.r6">[6]</xref></p>
        <p>A few cases of transient, reversible hepatic transaminase elevations&#x000a0;during cetirizine therapy have been reported in the literature. Some reports of hepatitis with elevated bilirubin have also been documented. In postmarketing studies, rare, potentially severe adverse events, including severe hypotension, anaphylaxis, hemolytic anemia, cholestasis, orofacial dyskinesia, glomerulonephritis, hepatitis, stillbirth, and thrombocytopenia,&#x000a0;have been reported.<xref ref-type="bibr" rid="article-19266.r30">[30]</xref></p>
        <p>The most common adverse reactions to ophthalmic formulations&#x000a0;include local pain at the instillation site, ocular hyperemia, and decreased visual acuity.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients should&#x000a0;be advised not to use cetirizine concurrently with alcohol or other CNS&#x000a0;depressants, such as benzodiazepines or opioids, as&#x000a0;this combination may&#x000a0;result in dose-related sedation.<xref ref-type="bibr" rid="article-19266.r31">[31]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pitolisant is a histamine-3 receptor competitive antagonist and inverse agonist used in patients with narcolepsy. Concurrent use with antihistamines like cetirizine may diminish the therapeutic efficacy of pitolisant.&#x000a0;This combination should be avoided.<xref ref-type="bibr" rid="article-19266.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cetirizine&#x000a0;decreases&#x000a0;gabapentin plasma concentrations and&#x000a0;reduces systemic exposure to gabapentin. However, gabapentin is a CNS depressant. Pharmacodynamic synergism between these 2 drugs may lead to additional and observable CNS depression.<xref ref-type="bibr" rid="article-19266.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cetirizine is a substrate of&#x000a0;P-glycoprotein, and verapamil is an inhibitor of P-glycoprotein. Concurrent administration of both drugs&#x000a0;prevents the efflux of cetirizine from the CNS and increases antihistaminic activity.<xref ref-type="bibr" rid="article-19266.r19">[19]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cetirizine should not be administered with erdafitinib, an inhibitor of P-glycoprotein (ABCB1, MDR1).<xref ref-type="bibr" rid="article-19266.r34">[34]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19266.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cetirizine is contraindicated in&#x000a0;patients with a known hypersensitivity to it or any of its ingredients. Cetirizine is also contraindicated in anyone with a known hypersensitivity to hydroxyzine, as cetirizine is a metabolite of hydroxyzine.<xref ref-type="bibr" rid="article-19266.r35">[35]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>There are few well-controlled human studies on cetirizine in pregnant mothers, although these showed it to be safe during pregnancy in animal studies. First-generation antihistamines, diphenhydramine, and doxylamine are safest to use during pregnancy.&#x000a0;However, first-generation antihistamines are more likely than second-generation antihistamines to cause somnolence; clinicians should counsel the patients regarding the potential adverse effects of the medication they choose to take during pregnancy.<xref ref-type="bibr" rid="article-19266.r24">[24]</xref></p>
      </sec>
      <sec id="article-19266.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients taking cetirizine require monitoring for the relief of symptoms.&#x000a0;Healthcare team members&#x000a0;should also monitor patients for adverse effects such as fatigue and somnolence in adults and headaches in children.</p>
        <p>The kidney primarily excretes cetirizine; as a result, the risk of toxicity is typically higher in patients with impaired renal function. Patients with renal impairment should take a lower medication dosage in their age bracket.<xref ref-type="bibr" rid="article-19266.r36">[36]</xref></p>
        <p>Liver function and enzymes should be closely monitored in patients with hepatic impairment. Healthcare providers should make dosage adjustments as needed for patients with hepatic impairment.<xref ref-type="bibr" rid="article-19266.r37">[37]</xref></p>
        <p>Cetirizine may be confused with sertraline (look-alike-sound-alike drugs).&#x000a0;Clinicians and pharmacists should be careful while prescribing and dispensing this drug.<xref ref-type="bibr" rid="article-19266.r38">[38]</xref></p>
      </sec>
      <sec id="article-19266.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Animal studies</bold>
</p>
        <p>Studies using rat models&#x000a0;have shown the minimal lethal dose of cetirizine to be approximately 460 times the maximum recommended daily dose for adults. The primary target of acute toxicity in rodents was the central nervous system. The primary target of multiple-dose toxicity in rodents was the liver.</p>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>A small number of cases of cetirizine overdose appear in the literature. However, many overdoses of cetirizine in children result from improper medication storage by adults living in the same home. Most overdose incidents in children resolve spontaneously, with drowsiness and sedation being the main adverse effects observed.&#x000a0;Drug-induced liver damage is common with numerous medications; there are reports of a small number of cases of cetirizine-induced liver damage. In all cases, liver enzyme values returned to normal after&#x000a0;cetirizine cessation.<xref ref-type="bibr" rid="article-19266.r39">[39]</xref>&#x000a0;An adult who overdosed on 150 mg cetirizine had somnolence but did not have abnormal blood chemistry, hematology results, or other clinical signs. An infant overdosed on&#x000a0;180 mg of cetirizine and experienced restlessness and irritability, followed by drowsiness.&#x000a0;Several hours after an accidental overdose of cetirizine, the 6-year-old&#x000a0;child presented with fixed and dilated pupils, tachycardia, agitation,&#x000a0;hyperthermia, and hallucinations consistent with anticholinergic toxicity.<xref ref-type="bibr" rid="article-19266.r40">[40]</xref>&#x000a0;</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no known specific antidote to cetirizine, and it&#x000a0;can not be effectively removed by dialysis. When overdosed on cetirizine, treatment should be supportive and symptomatic, considering any concomitantly ingested medications.<xref ref-type="bibr" rid="article-19266.r41">[41]</xref></p>
      </sec>
      <sec id="article-19266.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cetirizine&#x000a0;is a relatively safe and effective medication for treating allergic rhinitis, urticaria, and allergic conjunctivitis. As cetirizine is also available over the counter, prescribers should educate patients on the possible side effects, which include drowsiness,&#x000a0;fatigue, and dry mouth. Healthcare providers&#x000a0;should be careful when prescribing cetirizine to patients with impaired renal or hepatic function. Ophthalmologists&#x000a0;should educate contact lens wearers&#x000a0;on proper precautions and direct use of eye drops. Patients using eye drops should be informed that&#x000a0;local pain at the instillation site, ocular hyperemia, and decreased visual acuity are common adverse reactions with the ophthalmic formulation.</p>
        <p>Immunologists play a crucial role in the management of refractory urticaria. Nurses&#x000a0;should monitor therapeutic success and consult patients not to combine cetirizine with drugs that cause central nervous system depression. Pharmacists should perform regular and thorough medication&#x000a0;reconciliation and verify that the patient is not taking any medications or supplements that could exacerbate cetirizine's adverse effects. Clinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists&#x000a0;who prescribe or recommend cetirizine to patients should also provide information on the safe storage of cetirizine to prevent accidental overdose by children. If&#x000a0;the overdose of cetirizine is intentional, a psychiatrist should be consulted. Communication and collaboration among interprofessional teams can achieve the best patient outcomes and reduce healthcare service utilization costs.</p>
      </sec>
      <sec id="article-19266.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19266&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19266">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19266/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19266">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19266.s11">
        <title>References</title>
        <ref id="article-19266.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gehanno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bremard-Oury</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zeisser</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>1996</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>507</fpage>
            <page-range>507-12</page-range>
            <pub-id pub-id-type="pmid">8673684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guevara-Gutierrez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bonilla-Lopez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez-Arana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tlacuilo-Parra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of cetirizine versus cetirizine plus ranitidine in chronic urticaria: Double-blind randomized placebo-controlled study.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2015</year>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>548</fpage>
            <page-range>548-50</page-range>
            <pub-id pub-id-type="pmid">25886090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seidman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gurgel</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Baroody</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Dykewicz</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hackell</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ishman</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Krouse</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Malekzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mims</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Omole</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <collab>Guideline Otolaryngology Development Group. AAO-HNSF</collab>
            </person-group>
            <article-title>Clinical practice guideline: Allergic rhinitis.</article-title>
            <source>Otolaryngol Head Neck Surg</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>152</volume>
            <issue>1 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-43</page-range>
            <pub-id pub-id-type="pmid">25644617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thami</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy of cetirizine and levocetirizine in chronic idiopathic urticaria.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2007</year>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-4</page-range>
            <pub-id pub-id-type="pmid">17365263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dreyfus</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weldon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zuraw</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Blessing-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tilles</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The diagnosis and management of acute and chronic urticaria: 2014 update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2014</year>
            <month>May</month>
            <volume>133</volume>
            <issue>5</issue>
            <fpage>1270</fpage>
            <page-range>1270-7</page-range>
            <pub-id pub-id-type="pmid">24766875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malhotra</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Torkildsen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Jasek</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2019</year>
            <volume>13</volume>
            <fpage>403</fpage>
            <page-range>403-413</page-range>
            <pub-id pub-id-type="pmid">30858690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abella</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Blaiss</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stiell</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Herres</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Moellman</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Suner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Klausner</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Caterino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Intravenous Cetirizine Versus Intravenous Diphenhydramine for the Treatment of Acute Urticaria: A Phase III Randomized Controlled Noninferiority Trial.</article-title>
            <source>Ann Emerg Med</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>489</fpage>
            <page-range>489-500</page-range>
            <pub-id pub-id-type="pmid">32653333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Greenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ledford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nowak-Wegrzyn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sicherer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blessing-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tilles</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis--a practice parameter update 2015.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>341</fpage>
            <page-range>341-84</page-range>
            <pub-id pub-id-type="pmid">26505932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smoot</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marginean</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gervasi-Follmar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Comparing the Risk of Infusion-Related Reactions and Tolerability in Patients Given Cetirizine or Diphenhydramine Prior to Ocrelizumab Infusion (PRECEPT).</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2024</year>
            <month>Apr</month>
            <day>19</day>
            <volume>60</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">38674305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durham</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Thotakura</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Herrington</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>1396</fpage>
            <page-range>1396-1401</page-range>
            <pub-id pub-id-type="pmid">30419768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reinhart</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Casanegra</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Rooke</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Sartori-Valinotti</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Klaas</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Bridging the gap in BASCULE syndrome: A retrospective case series of a recently described clinical entity.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2024</year>
            <season>Jan-Feb</season>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>46</fpage>
            <page-range>46-50</page-range>
            <pub-id pub-id-type="pmid">38014569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seifian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Safari Giv</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Abdollahimajd</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Namazi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Topical cetirizine for the management of androgenic alopecia: Results of a pilot study.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>708</fpage>
            <page-range>708-710</page-range>
            <pub-id pub-id-type="pmid">37697482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chatelain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Massingham</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Hammarlund-Udenaes</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu).</article-title>
            <source>Drug Metab Dispos</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>318</fpage>
            <page-range>318-23</page-range>
            <pub-id pub-id-type="pmid">16303872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tashkin</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Brik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine inhibition of histamine-induced bronchospasm.</article-title>
            <source>Ann Allergy</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>59</volume>
            <issue>6 Pt 2</issue>
            <fpage>49</fpage>
            <page-range>49-52</page-range>
            <pub-id pub-id-type="pmid">2892450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciprandi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tosca</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Milanese</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ricca</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine reduces cytokines and inflammatory cells in children with perennial allergic rhinitis.</article-title>
            <source>Eur Ann Allergy Clin Immunol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>237</fpage>
            <page-range>237-40</page-range>
            <pub-id pub-id-type="pmid">15329007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Townley</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Use of cetirizine to investigate non-H1 effects of second-generation antihistamines.</article-title>
            <source>Ann Allergy</source>
            <year>1992</year>
            <month>Feb</month>
            <volume>68</volume>
            <issue>2</issue>
            <fpage>190</fpage>
            <page-range>190-6</page-range>
            <pub-id pub-id-type="pmid">1346737</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <article-title>OTC drugs for seasonal allergies.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2019</year>
            <month>Apr</month>
            <day>22</day>
            <volume>61</volume>
            <issue>1570</issue>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">31169808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jurkiewicz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Czarnecka-Operacz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Pawliczak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woro&#x00144;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moniuszko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Emeryk</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role and choice criteria of antihistamines in allergy management - expert opinion.</article-title>
            <source>Postepy Dermatol Alergol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>397</fpage>
            <page-range>397-410</page-range>
            <pub-id pub-id-type="pmid">28035215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Theunissen</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Vermeeren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Ruitenbeek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stiers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Toennes</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Ramaekers</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>The role of P-glycoprotein in CNS antihistamine effects.</article-title>
            <source>Psychopharmacology (Berl)</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>229</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-19</page-range>
            <pub-id pub-id-type="pmid">23564211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corsico</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Licari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marseglia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Miraglia Del Giudice</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peroni</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Salpietro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ciprandi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Focus on the cetirizine use in clinical practice: a reappraisal 30&#x02009;years later.</article-title>
            <source>Multidiscip Respir Med</source>
            <year>2019</year>
            <volume>14</volume>
            <fpage>40</fpage>
            <pub-id pub-id-type="pmid">31827796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DuBuske</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Dose-ranging comparative evaluation of cetirizine in patients with seasonal allergic rhinitis.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>345</fpage>
            <page-range>345-54</page-range>
            <pub-id pub-id-type="pmid">7719897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jobst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van den Wijngaart</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van de Venne</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Assessment of the efficacy and safety of three dose levels of cetirizine given once daily in children with perennial allergic rhinitis.</article-title>
            <source>Allergy</source>
            <year>1994</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>8</issue>
            <fpage>598</fpage>
            <page-range>598-604</page-range>
            <pub-id pub-id-type="pmid">7653736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <chapter-title>Cetirizine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>1</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golembesky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooney</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boev</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schlit</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Bentz</surname>
                <given-names>JWG</given-names>
              </name>
            </person-group>
            <article-title>Safety of cetirizine in pregnancy.</article-title>
            <source>J Obstet Gynaecol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>940</fpage>
            <page-range>940-945</page-range>
            <pub-id pub-id-type="pmid">29565188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzotta</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Loebstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treating allergic rhinitis in pregnancy. Safety considerations.</article-title>
            <source>Drug Saf</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>361</fpage>
            <page-range>361-75</page-range>
            <pub-id pub-id-type="pmid">10230583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis.</article-title>
            <source>Front Pediatr</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>940213</fpage>
            <pub-id pub-id-type="pmid">36090559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>FQ</given-names>
              </name>
              <name>
                <surname>Blender</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vantipalli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ocular benzalkonium chloride exposure: problems and solutions.</article-title>
            <source>Eye (Lond)</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>361</fpage>
            <page-range>361-368</page-range>
            <pub-id pub-id-type="pmid">34262161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozdemir</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Karadag</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Selvi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boysan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bilgili</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Aydin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Onder</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety.</article-title>
            <source>Int J Psychiatry Clin Pract</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-8</page-range>
            <pub-id pub-id-type="pmid">24673474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nayak</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>LaForce</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Urdaneta</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>222</fpage>
            <page-range>222-230</page-range>
            <pub-id pub-id-type="pmid">28441993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajput</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baerg</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine-induced dystonic movements.</article-title>
            <source>Neurology</source>
            <year>2006</year>
            <month>Jan</month>
            <day>10</day>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>143</fpage>
            <page-range>143-4</page-range>
            <pub-id pub-id-type="pmid">16401869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vermeeren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramaekers</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>O'Hanlon</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females.</article-title>
            <source>J Psychopharmacol</source>
            <year>2002</year>
            <month>Mar</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">11949773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarfraz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Okuampa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alvarez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kakazu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.</article-title>
            <source>Health Psychol Res</source>
            <year>2022</year>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>34222</fpage>
            <pub-id pub-id-type="pmid">35774905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costa</surname>
                <given-names>ACC</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Lauretti</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>de Lima Benzi</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Zanelli</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Barz</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ciarimboli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Moraes</surname>
                <given-names>NV</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine Reduces Gabapentin Plasma Concentrations and Effect: Role of Renal Drug Transporters for Organic Cations.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>1076</fpage>
            <page-range>1076-1086</page-range>
            <pub-id pub-id-type="pmid">32149389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>ZX</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>XD</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>QX</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>955</fpage>
            <pub-id pub-id-type="pmid">32670878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bizikova</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papich</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Olivry</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs.</article-title>
            <source>Vet Dermatol</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>348</fpage>
            <page-range>348-57</page-range>
            <pub-id pub-id-type="pmid">18980631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matzke</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Awni</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Halstenson</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency.</article-title>
            <source>Ann Allergy</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>59</volume>
            <issue>6 Pt 2</issue>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">2892446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <chapter-title>Cetirizine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">31643739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.</article-title>
            <source>J Am Med Inform Assoc</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>872</fpage>
            <page-range>872-884</page-range>
            <pub-id pub-id-type="pmid">29800453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coskun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yavasoglu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yasa</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Culhaci</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yukselen</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine-induced hepatotoxicity: case series and review of the literature.</article-title>
            <source>Gastroenterol Rep (Oxf)</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>228</fpage>
            <page-range>228-230</page-range>
            <pub-id pub-id-type="pmid">27576471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karagiannis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salzman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Unintentional cetirizine overdose causing anticholinergic syndrome.</article-title>
            <source>Am J Emerg Med</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>52</volume>
            <fpage>270.e1</fpage>
            <page-range>270.e1-270.e3</page-range>
            <pub-id pub-id-type="pmid">34474941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19266.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ridout</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Tariq</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Cetirizine overdose in a young child.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>99</volume>
            <issue>6 Pt 1</issue>
            <fpage>860</fpage>
            <page-range>860-1</page-range>
            <pub-id pub-id-type="pmid">9215262</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
